Hypothesis

In aged individuals, the germinal center microenvironment skews activation‑induced cytidine deaminase (AID) activity away from complementarity‑determining regions (CDRs) through chronic low‑grade IFN‑γ signaling and PP2A‑mediated E47 suppression, while aged B cells simultaneously drive CD4+ T follicular helper (Tfh) senescence via MHC II‑dependent antigen presentation, creating a feedback loop that further reduces IFN‑γ‑regulated DNA repair factors. This combined intrinsic‑extrinsic defect yields fewer replacement mutations in CDRs and reduced junctional diversity, accounting for the observed decline in antibody quality despite preserved somatic hypermutation frequency when aged B cells are placed in a young host.

Mechanistic Basis

• Inflamed microenvironment: Aging-associated elevation of IFN‑γ induces expression of the DNA repair enzyme UNG2 and shifts the balance of base excision repair toward error‑free pathways at AID‑generated uracils, favoring transitions at hotspot motifs located outside CDRs. Simultaneously, IFN‑γ upregulates PP2A activity, which destabilizes the transcription factor E47, lowering AID overall levels but leaving enough enzyme to act on accessible, non‑ CDR DNA.
• B‑cell‑driven Tfh senescence: Aged B cells present self‑antigens and persistent viral peptides on MHC II, delivering chronic TCR stimulation to CD4+ T cells. This engages inhibitory receptors (PD‑1, LAG‑3) and reduces IL‑21 production, a cytokine known to promote AID targeting to CDRs via STAT3‑dependent chromatin remodeling at Ig loci.
• Feedback loop: Diminished IL‑21 from senescent Tfh further lowers AID expression and exacerbates the PP2A‑E47 axis, while reduced germinal center size limits clonal competition, allowing low‑affinity B cells with off‑target mutations to persist.

Predictions and Experimental Tests

1. IFN‑γ blockade restores CDR‑biased mutation: Treating aged mice with anti‑IFN‑γ antibodies before immunization will increase the ratio of replacement to silent mutations in CDRs of vaccine‑induced antibodies, without changing overall mutation frequency. (Test via high‑throughput Ig sequencing of germinal center B cells.)
2. PP2A inhibition rescues AID expression and CDR targeting: Administering a selective PP2A inhibitor (e.g., LB‑100) to aged mice will elevate E47 levels, increase AID transcription, and shift mutation hotspots back toward CDRs, mimicking the phenotype seen when aged B cells are transferred into young hosts. (Measure AID mRNA/protein in sorted B cells and analyze mutation patterns.)
3. MHC II blockade breaks the B‑to‑Tfh senescence loop: Conditional deletion of MHC II on B cells in aged mice will preserve Tfh IL‑21 production, improve germinal center size, and enhance CDR replacement mutations, even in the presence of elevated IFN‑γ. (Use CD19‑Cre × MHCII^fl/fl mice and assess Tfh phenotype and antibody quality.)
4. Longitudinal CDR3 tracking reveals divergent outcomes: In humans, elderly individuals who receive mRNA boosters will show transient increases in CDR3 length diversity and CDR replacement mutations only when serum IFN‑γ remains low; high baseline IFN‑γ predicts poor quality responses despite comparable neutralization titers. (Correlate pre‑vaccination IFN‑γ levels with post‑vaccination Ig‑seq metrics.)

Potential Implications

If validated, this model reframes age‑related humoral decline as a reversible dysregulation of AID targeting rather than a fixed loss of mutational capacity. It suggests combinatorial therapies—cytokine modulation, phosphatase inhibition, and MHC II‑directed interventions—could rescue vaccine efficacy in older adults by restoring the spatial precision of somatic hypermutation.